Immunological characteristics of systemic lupus erythematosus (SLE) include polyclonal B-cell activation and production of specific autoantibodies. However, the autoimmune response is highly restricted to only a few antigens, indicating that there are mechanisms to specifically select target antigens. Autoantibodies to small nuclear ribonucleoproteins (snRNPs: Sm and nRNP) are frequently produced in SLE, MRL mice, and pristane-treated normal mice. In pristane-treated mice, the U1-70K, which has an unusually high arginine content (21%), appears central to the autoimmune process. Arginine is consumed by activated macrophages and arginases in inflammatory sites. In addition, L-canavanine, a non-protein amino acid homologue of L-arginine present in higher plants, may be efficiently incorporated into proteins, producing aberrant proteins that could create cryptic epitopes capable of triggering autoimmunity. In this study, we will investigate why U1 snRNPs are selectively targeted in pristane-induced lupus. We hypothesize that the arginine-rich U1-70K is aberrant in arginine-deficient pristane granulomas, generating cryptic epitopes that initiate autoimmunity.
In aim 1, whether arginine is deficient in pristane-treated mice will be examined by amino acids analysis. Arginine metabolism (uptake, consumption, and reconversion) also will be evaluated.
In Aim 2, U1-70K synthesized in arginine-deficient conditions and in the presence of L-canavanine in vitro will be evaluated for modifications by immunoprecipitation, amino acid analysis, and mass spectrometry. U1-70K from cells in pristane-treated mice also will be examined.
In Aim 3, whether aberrant UlsnRNPs (arginine-deficient, L-canavanine containing) can trigger a specific autoimmune response will be investigated by immunizing mice with purified UlsnRNPs or apoptotic cells derived from these conditions.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-RJB-A (O1))
Program Officer
Gretz, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Florida
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Lee, Pui Y; Kumagai, Yutaro; Li, Yi et al. (2008) TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 205:2995-3006
Yamasaki, Yoshioki; Narain, Sonali; Yoshida, Hideo et al. (2007) Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 56:596-604
Kelly, Kindra M; Zhuang, Haoyang; Nacionales, Dina C et al. (2006) ""Endogenous adjuvant"" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 54:1557-67
Nacionales, Dina C; Kelly, Kindra M; Lee, Pui Y et al. (2006) Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 168:1227-40
Akaogi, Jun; Barker, Tolga; Kuroda, Yoshiki et al. (2006) Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmun Rev 5:429-35
Kuroda, Yoshiki; Ono, Nobutaka; Akaogi, Jun et al. (2006) Induction of lupus-related specific autoantibodies by non-specific inflammation caused by an intraperitoneal injection of n-hexadecane in BALB/c mice. Toxicology 218:186-96
Jakymiw, Andrew; Ikeda, Keigo; Fritzler, Marvin J et al. (2006) Autoimmune targeting of key components of RNA interference. Arthritis Res Ther 8:R87
Ikeda, Keigo; Satoh, Minoru; Pauley, Kaleb M et al. (2006) Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Methods 317:38-44
Mizutani, Akiei; Shaheen, Victoria M; Yoshida, Hideo et al. (2005) Pristane-induced autoimmunity in germ-free mice. Clin Immunol 114:110-8
Kuroda, Yoshiki; Nacionales, Dina C; Akaogi, Jun et al. (2004) Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 58:325-37

Showing the most recent 10 out of 11 publications